These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12001999)

  • 21. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is an HIV vaccine possible?
    McMichael AJ; Hanke T
    Nat Med; 1999 Jun; 5(6):612-4. PubMed ID: 10371492
    [No Abstract]   [Full Text] [Related]  

  • 24. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
    Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
    Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of multivalent genome-wide T cell responses in HLA-A*0201 transgenic mice by an HIV-1 expression library immunization (ELI) vaccine.
    Singh RA; Barry MA
    Res Initiat Treat Action; 2003; 8(2):17-9. PubMed ID: 12845772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hitting HIV where it hurts: an alternative approach to HIV vaccine design.
    Altfeld M; Allen TM
    Trends Immunol; 2006 Nov; 27(11):504-10. PubMed ID: 16997629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Li W; Li S; Hu Y; Tang B; Cui L; He W
    Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins.
    Huang XL; Fan Z; Zheng L; Borowski L; Li H; Thomas EK; Hildebrand WH; Zhao XQ; Rinaldo CR
    J Infect Dis; 2003 Jan; 187(2):315-9. PubMed ID: 12552458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on the immunogenicity of HIV-1 gag vaccine].
    Jiang WZ; Jin NY; Li ZJ; Zhang LS
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):272-3. PubMed ID: 15193215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disappointing data scuttle plans for large-scale AIDS vaccine trial.
    Cohen J
    Science; 2002 Mar; 295(5560):1616-7. PubMed ID: 11872804
    [No Abstract]   [Full Text] [Related]  

  • 34. Reservoirs dog AIDS therapy.
    Smaglik P
    Nature; 2000 May; 405(6784):270-2. PubMed ID: 10830936
    [No Abstract]   [Full Text] [Related]  

  • 35. Is AIDS vaccine research at a turning point?
    Levy JP
    J Hum Virol; 2000; 3(2):83-7. PubMed ID: 10850894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1999: a time to re-evaluate AIDS vaccine strategies.
    Ruprecht RM; Hofmann-Lehmann R; Rasmussen RA; Vlasak J; Xu W
    J Hum Virol; 2000; 3(2):88-93. PubMed ID: 10850895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunology and the elusive AIDS vaccine.
    Virgin HW; Walker BD
    Nature; 2010 Mar; 464(7286):224-31. PubMed ID: 20220841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A winding road towards an HIV vaccine.
    Rowland-Jones S
    Eur J Immunol; 2008 Jan; 38(1):13-4. PubMed ID: 18286707
    [No Abstract]   [Full Text] [Related]  

  • 39. Prospects for an AIDS vaccine: three big questions, no easy answers.
    Garber DA; Silvestri G; Feinberg MB
    Lancet Infect Dis; 2004 Jul; 4(7):397-413. PubMed ID: 15219551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunology in AIDS in 1990.
    Sela M
    AIDS; 1990; 4 Suppl 1():S9-14. PubMed ID: 1983804
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.